

# Lupus Anticoagulant Confirmation Reagent™

Catalog No. 102516

## Product Applications:

- Clinical Laboratories
- Pharmaceutical Laboratories
- Contract Research Organizations (CROs)
- Clinical Trials
- Research Laboratories
- Hemophilia Centers
- Regional Blood Centers
- Reference Laboratories

## Facing Unexpected or Prolonged APTT Results?

### Confirm Lupus Anticoagulant with LA-CR

**Lupus Anticoagulant Confirmation Reagent™ (LA-CR)** is a platelet phospholipid solution used to perform the platelet neutralization procedure. Use of the LA-CR test kit confirms that previous laboratory results have correctly flagged a sample as containing the lupus anticoagulant.



Net Contents: 5 x 1.0mL

- **Optimized Source of Platelet Phospholipids**
- **Used to Perform Platelet Neutralization Procedure (PNP) Needed as Part of a Multi-Test Investigation for the Presence of the Lupus Anticoagulant**

Lupus anticoagulant is the most common cause of acquired thrombophilia. The incidence of lupus anticoagulant in the general population is 1% to 2%. To be considered clinically significant, a lupus anticoagulant must be present on two occasions at least six to eight weeks apart.

**Meets  
ISTH  
Guidelines**


Based on recommendations from the **International Society for Thrombosis and Hemostasis (ISTH)**, three criteria must be met to confirm lupus anticoagulant:

- Demonstration of prolongation of a phospholipid dependent clotting assay
- Demonstration using mixing studies or factor assays that an inhibitor is present
- Demonstration that the inhibitor is phospholipid dependent


## Who should be screened for Lupus Anticoagulant?

- Individuals who suffer venous thrombosis, especially if idiopathic
- Individuals who suffer an arterial occlusive event (e.g. myocardial Infarction [MI] or stroke) before the age of 50 years
- Individuals greater than 50 years of age without typical risk factors for arterial occlusive disease who suffer MI or stroke
- All patients with systemic lupus erythematosus
- Women who suffer 3 or more first trimester pregnancy losses or a single unexplained fetal loss in the second or third trimester
- Women who suffer severe preeclampsia or intrauterine growth retardation without a known provoker

### Phospholipid dependent reactions are blocked by the action of antiphospholipid antibodies at two key points.



### Factor Va inactivation (control regulation) by inhibition of Protein C mechanism.



Hill G S, Nochy D JASN 2007;18:2461-2464


 155 Gibraltar Road  
 Horsham, PA 19044 USA

Worldwide: +1 215-441-4000

USA: 1-800-257-3282

Fax Worldwide: +1 215-443-8820

customer.service@biodatacorp.com



An ISO 13485 Registered Company

[www.biodatacorp.com](http://www.biodatacorp.com)

 mdi Europa GmbH  
 Langenhagener Str. 71  
 D-30855 Langenhagen  
 GERMANY

 Alpha Laboratories  
 40 Parham Drive Eastleigh  
 SO50 4NU Hampshire  
 UNITED KINGDOM
